TY - JOUR
T1 - Hepatitis B Immune Globulin
T2 - Effectiveness in Prevention of Dialysis-Associated Hepatitis
AU - Prince, Alfred M.
AU - Szmuness, Wolf
AU - Mann, Margaret K.
AU - Vyas, Girish N.
AU - Grady, George F.
AU - Shapiro, Fred L.
AU - Suki, Wadi N.
AU - Friedman, Eli A.
AU - Stenzel, Kurt H.
PY - 1975/11/20
Y1 - 1975/11/20
N2 - A randomized, double blind, multicenter study of hepatitis prevention by immune serum globulin with high anti-HBs titer (hepatitis B immune globulin) was carried out among 318 new patients and 296 staff members of renal dialysis units. Three milliliters of high titer globulin, repeated at 4 months, was compared with equal doses of intermediate or normal titer globulin. Among staff members, the cumulative percentages developing hepatitis or HBs Ag. or both, within 8 months were 6.9, 11.7, and 11.1 in the high, intermediate, and normal titer groups respecively. The lower incidence associated with high titer globulin was not significant (P<0.05). However, among the patients the respective percentages were 7.9, 21.3, and 23.1 and the lower incidence in the high titer globulin group was significant (P<0.01).
AB - A randomized, double blind, multicenter study of hepatitis prevention by immune serum globulin with high anti-HBs titer (hepatitis B immune globulin) was carried out among 318 new patients and 296 staff members of renal dialysis units. Three milliliters of high titer globulin, repeated at 4 months, was compared with equal doses of intermediate or normal titer globulin. Among staff members, the cumulative percentages developing hepatitis or HBs Ag. or both, within 8 months were 6.9, 11.7, and 11.1 in the high, intermediate, and normal titer groups respecively. The lower incidence associated with high titer globulin was not significant (P<0.05). However, among the patients the respective percentages were 7.9, 21.3, and 23.1 and the lower incidence in the high titer globulin group was significant (P<0.01).
UR - http://www.scopus.com/inward/record.url?scp=0016824226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016824226&partnerID=8YFLogxK
U2 - 10.1056/NEJM197511202932103
DO - 10.1056/NEJM197511202932103
M3 - Article
C2 - 1101066
AN - SCOPUS:0016824226
SN - 0028-4793
VL - 293
SP - 1063
EP - 1067
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 21
ER -